Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Tweet
Share
E-mail
The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. REUTERS/Brendan McDermid
Aug 28 (Reuters) - Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
• Kimberly-Clark announced the takeover in November last year.
• The deal was expected to close in the second half of 2026, it said at the time.
• Kimberly-Clark forecast $2.1 billion in annual cost savings from the deal.
• The addition of Kenvue's vast portfolio of brands from Listerine mouth wash to skincare names like Aveeno and Neutrogena is expected to bring in annual revenues of roughly $32 billion for the combined company, it said.
(Reporting by Bart Meijer;Editing by Sudip Kar-Gupta)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Even Cuba's stray cats are feeling the heat as crisis deepens
- Bank of Canada to hold rates for another year, wait for more stability on trade: Reuters poll
- Marvell shares slide as concerns over timing of Google AI deal revenue eclipse strong results
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
